Anemia itself is not an autoimmune disease. It’s a broad term for having too few healthy red blood cells, and most cases stem from iron deficiency, blood loss, or chronic illness with no autoimmune component at all. However, several specific types of anemia are genuinely autoimmune, meaning the immune system directly attacks red blood cells or the cells that produce them. Understanding which types fall into each category matters because the causes, treatments, and outlook are very different.
Types of Anemia That Are Autoimmune
Three major forms of anemia have a confirmed autoimmune basis: autoimmune hemolytic anemia (AIHA), pernicious anemia, and acquired aplastic anemia. Each involves a different immune mistake, but all share the core feature of the body’s defenses turning against its own blood system.
Autoimmune hemolytic anemia occurs when the immune system produces antibodies that latch onto red blood cells and mark them for destruction. It’s rare, affecting roughly 1 to 7 people per 100,000 each year in the United States, with an overall prevalence of about 17 per 100,000. AIHA is subdivided into seven distinct types based on the kind of antibody involved and the temperature at which it becomes active. The two most common are warm-antibody AIHA (where antibodies bind at normal body temperature) and cold agglutinin disease (where antibodies activate in cooler parts of the body like the fingers, nose, and ears).
Pernicious anemia is a different mechanism entirely. Rather than destroying red blood cells directly, the immune system attacks the stomach cells that produce intrinsic factor, a protein essential for absorbing vitamin B12. Without enough B12, the body makes abnormally large, dysfunctional red blood cells. Two types of autoantibodies drive this: one blocks B12 from binding to intrinsic factor in the first place, and another binds to the B12-intrinsic factor pair and prevents the gut from absorbing it. About 25% of people with autoimmune gastritis eventually develop pernicious anemia.
Acquired aplastic anemia targets the source rather than the product. Immune T cells attack the stem cells in bone marrow that give rise to all blood cells, not just red blood cells. This leads to dangerously low counts of red cells, white cells, and platelets simultaneously. Researchers have confirmed that specific immune cells from aplastic anemia patients carry receptors capable of recognizing and killing their own blood-forming stem cells, driven by inflammatory signaling molecules.
Types of Anemia That Are Not Autoimmune
The vast majority of anemia cases worldwide have nothing to do with the immune system. Iron deficiency anemia, the most common form globally, results from not getting enough iron through diet, losing iron through bleeding (heavy periods, ulcers, or surgery), or being unable to absorb iron properly. In iron deficiency, the body’s iron storage protein (ferritin) drops below 30 ng/ml and the percentage of iron carried in the blood falls below 16%. No antibodies are involved.
Anemia of chronic disease (sometimes called anemia of inflammation) looks superficially similar but works differently. Chronic infections, cancer, kidney disease, or inflammatory conditions cause the body to lock iron away in storage rather than releasing it for red blood cell production. Ferritin levels are actually elevated, often above 200 ng/ml, because the iron is being hoarded, not depleted. This form of anemia is a consequence of inflammation, not a direct autoimmune attack on blood cells.
Genetic anemias like sickle cell disease and thalassemia are inherited conditions affecting hemoglobin structure or production. They are present from birth and are not caused by immune dysfunction.
How Warm and Cold AIHA Destroy Red Blood Cells
In warm-antibody AIHA, which accounts for the majority of autoimmune hemolytic cases, IgG antibodies coat red blood cells at normal body temperature. Immune cells in the spleen recognize these coated cells, latch onto the antibody, and either swallow the red blood cell whole or tear off pieces of its membrane. The damaged cells become small, rigid spheres (called microspherocytes) that get trapped and destroyed the next time they pass through the spleen. This destruction happens outside the bloodstream, primarily in the spleen and sometimes the liver.
Cold agglutinin disease works through a different antibody class, IgM, which activates at temperatures below body temperature. IgM antibodies are much more efficient at triggering the complement system, a cascade of proteins that can punch holes directly in cell membranes. This means cold AIHA causes more destruction inside the bloodstream itself. Symptoms often flare in cold weather or after handling cold objects, because the antibodies become most active when blood cools as it circulates through the skin and extremities.
Paroxysmal cold hemoglobinuria is the rarest and most dramatic form. Its antibodies bind to red blood cells in the cold but only activate the full complement destruction sequence when the blood warms back up to core body temperature. This creates sudden, intense episodes of red blood cell destruction.
Conditions That Trigger Secondary AIHA
AIHA can appear on its own (primary) or be triggered by an underlying disease (secondary). The distinction matters because treating the underlying condition often helps control the anemia. Common triggers include lupus, rheumatoid arthritis, and Hashimoto’s thyroiditis. Blood cancers, particularly chronic lymphocytic leukemia and non-Hodgkin lymphoma, are also frequent culprits. Infections with Epstein-Barr virus, cytomegalovirus, hepatitis viruses, and HIV can set off AIHA as well. Certain medications can also trigger drug-induced immune hemolytic anemia, which mimics warm AIHA and resolves when the drug is stopped.
How Autoimmune Anemia Is Diagnosed
The key test for AIHA is the direct antiglobulin test, commonly known as the Coombs test. A blood sample is washed and mixed with a reagent that detects antibodies or complement proteins stuck to the surface of red blood cells. If the red blood cells clump together (agglutinate), the test is positive, confirming that something in the immune system is coating and targeting those cells. Results are graded on a scale from weak (tiny aggregates in a cloudy background) to strong (a single visible clump of cells). Even microscopic clumping of three to five cells counts as positive.
The specific pattern of the Coombs test helps identify which type of AIHA is present. Finding IgG alone on the red blood cells points to warm AIHA. Finding only complement (C3d) suggests cold agglutinin disease or paroxysmal cold hemoglobinuria. Finding both IgG and complement indicates mixed AIHA. Some patients have a negative Coombs test despite genuine autoimmune destruction, because antibody levels fall below the test’s detection threshold.
For pernicious anemia, diagnosis involves blood tests showing low B12 levels alongside elevated methylmalonic acid and homocysteine, plus antibodies against intrinsic factor or parietal cells. Aplastic anemia is diagnosed through a bone marrow biopsy showing empty or severely depleted marrow.
Treatment and Relapse
Treatment differs sharply depending on the type of autoimmune anemia. For warm AIHA, steroids are the standard first step. Most people start responding within one to three weeks as the steroids suppress the immune attack. If steroids don’t work or the anemia returns when they’re tapered, options include surgical removal of the spleen (effective in roughly two out of three patients) or a targeted antibody therapy called rituximab, which works in about 80 to 90% of cases. For cold agglutinin disease, steroids are less effective, and rituximab is now recommended as the first-line treatment.
Relapse is a significant reality. In one study of AIHA patients, 57.7% relapsed, with a median remission of just 9 months before the first relapse. Patients with cold antibodies had the highest relapse rate at nearly 87%, while those whose Coombs test turned negative fared best at about 31%. Higher antibody levels also predicted more frequent relapse. Combining steroids with a second immunosuppressant reduced relapse rates compared to steroids alone.
Pernicious anemia is managed with lifelong B12 supplementation, either through injections or high-dose oral supplements, which bypasses the absorption problem entirely. Aplastic anemia requires more aggressive immune suppression or, in severe cases, a bone marrow transplant to replace the destroyed stem cells.
How to Tell the Difference
If you’ve been diagnosed with anemia and are wondering whether yours is autoimmune, the blood work tells the story. Iron deficiency shows low ferritin and low iron saturation. Anemia of chronic inflammation shows high ferritin with low iron saturation, reflecting iron being trapped rather than absent. Autoimmune hemolytic anemia shows signs of active red blood cell destruction: elevated bilirubin, high lactate dehydrogenase, low haptoglobin, and a positive Coombs test. Pernicious anemia shows abnormally large red blood cells on a blood smear alongside low B12 and specific autoantibodies.
These patterns are distinct enough that standard lab tests can usually sort autoimmune from non-autoimmune anemia without invasive procedures. The type of anemia determines the treatment path, so getting the right diagnosis early avoids months of taking iron supplements that won’t help if the real problem is immune destruction.